You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Moodys
Dow
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BC-3781

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BC-3781?

BC-3781 is an investigational drug.

There have been 4 clinical trials for BC-3781. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.

The most common disease conditions in clinical trials are Pneumonia, Pneumonia, Bacterial, and Infection. The leading clinical trial sponsors are Nabriva Therapeutics AG and [disabled in preview].

There are five US patents protecting this investigational drug and one hundred and thirteen international patents.

Recent Clinical Trials for BC-3781
TitleSponsorPhase
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With PneumoniaNabriva Therapeutics AGPhase 3
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With PneumoniaNabriva Therapeutics AGPhase 3
Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy SubjectsNabriva Therapeutics AGPhase 1

See all BC-3781 clinical trials

Clinical Trial Summary for BC-3781

Top disease conditions for BC-3781
Top clinical trial sponsors for BC-3781

See all BC-3781 clinical trials

US Patents for BC-3781

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BC-3781   Start Trial Crystal structure of the large ribosomal subunit from S. aureus Yeda Research and Development Co. Ltd. (Rehovot, IL)   Start Trial
BC-3781   Start Trial Pleuromutilin derivatives having antibacterial activity Biochemie Gesellschaft m.b.H. (Kundl, AT)   Start Trial
BC-3781   Start Trial Pleuromutilin derivatives for the treatment of diseases mediated by microbes Nabriva Therapeutics AG (Vienna, AT)   Start Trial
BC-3781   Start Trial Pleuromutilin derivatives for the treatment of diseases mediated by microbes Nabriva Therapeutics AG (Vienna, AT)   Start Trial
BC-3781   Start Trial Process for the preparation of pleuromutilins NABRIVA THERAPEUTICS AG (Vienna, AT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BC-3781

Drugname Country Document Number Estimated Expiration Related US Patent
BC-3781 European Patent Office 3250585 2035-01-29   Start Trial
BC-3781 World Intellectual Property Organization (WIPO) 2016120868 2035-01-29   Start Trial
BC-3781 Argentina 029590 2020-07-11   Start Trial
BC-3781 Austria 408596 2020-07-11   Start Trial
BC-3781 Australia 2001276389 2020-07-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Moodys
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.